All Wales advice on oral anticoagulation for non-valvular atrial fibrillation

Previously published in March 2020, this guidance focuses on treatment of patients with non-valvular atrial fibrillation (NVAF) and incorporates a risk/benefit assessment tool, and a one-page summary for Welsh healthcare practitioners choosing a direct oral anticoagulant in this patient population.

In February 2022, this guideline has been updated to reflect changes in NICE guidance. This includes incorporating the ORBIT bleeding risk tool as part of the risk/benefit assessment tool and repositioning direct oral anticoagulants (DOACs) before vitamin K antagonists (e.g. warfarin) in the treatment pathway.

(February 2022)